‘Not desperate’: Novo Nordisk’s Metsera miss puts strategy in spotlight
Ozempic maker’s new boss says he has a ‘fantastic pipeline’ after losing battle for biotech
Related reading
There is only one winner in the Pfizer Novo Nordisk showdown
Fight for Metsera looks like 1980s corporate raider redux
Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera
Pfizer had struck deal in September to buy obesity-focused biotech
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies
Improved pitches from both large pharma groups expected to be revealed later on Tuesday
Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
Parvus shows interest in Danish drugmaker that is hunting for new chief following share price slump
Pfizer shows hardball mettle needed to win in 2025 M&A
Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk